Neurogen Corporation: Premium Company Profile

Publication Date	January 2008
Publisher	Datamonitor
Product Type	Databook
Pages	48
ISBN Number	not applicable
Product Code	DAT09411

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

Neurogen is a drug discovery and development company founded in 1987. The company established its presence in the pharmaceutical market by partnering with Pfizer and American Home Products in 1999. In addition, the company's proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), is the result of a successful collaboration with Merck for VR-1 research programs.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Neurogen is focused on developing small molecule drugs for disorders with unmet medical need, including insomnia, pain, obesity, depression and inflammation. The company utilizes its proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), for discovering and optimizing potential drug leads.

The key elements of the company's business strategy include: advancing clinical development of its product candidates, acquiring potential product candidates through licensing agreements and continue to maximize the success of VR-1 research program with Merck.

The company's total revenues declined at a CAGR of 11.1% during 2002-2006, from $15.7 million to $9.8 million. This represents an absolute total decline of -$5.9 million for total revenues. The decline is primarily due to the termination of the company's research collaboration with Aventis in September 2004.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Pipeline Products
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Neurogen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 1: Neurogen - Key Facts
- Table 2: Neurogen - Locations and Subsidiaries
- Table 3: Neurogen - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: Neurogen - Key Events Impacting Share Price Performance
- Table 5: Neurogen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: Neurogen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 7: Neurogen - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Neurogen - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Neurogen - Revenue Breakdown by Division, 2002-2006 ($ Mn)
- Table 10: Neurogen - in-house Pipeline Products
- Table 11: Neurogen - Collaboration Products
- Table 12: Neurogen - Forecast Sales, 2006-2010 ($ Mn)
- Table 13: Neurogen - Key Competitors
- Table 14: Neurogen - Key Suppliers
- Table 15: Neurogen - Key Clients
- Table 16: Neurogen - Key Shareholders
- Table 17: Neurogen - SWOT Analysis Summary
- Table 18: Neurogen - Value Chain Analysis
- Table 19: Neurogen - Scorecard
- Table 20: Neurogen - Key Employees
- Table 21: Neurogen - Financial and Operational Overview